Download - Allo -HSCT for ALL
林建廷
Cancer 2006;106:2657–63
55%
34%
5%
OS
25%Ph+
Standard risk
High risk
All pts
cHR pts
Risk stratification at diagnosis
Germany GMALL group◦ rt-PCR method, 105 pts in cHR with MRD(-) at enroll◦ No high WBC, not pro-B, pre-T, mature T, no poor
cyt◦ Median molecular to clinical relapse:9.5m
Blood. 2007;109:910-915
17/28(61%)
5/77(6%)
Haematologica 2008 Feb; 93(2):303-306.
Retrospective, 97 pts
Haematologica 2008 Feb; 93(2):303-306.
2-yr Leukemic-free survival Non-relapse mortality Relapse incidence
52%
42%
18%
18%@2yr for CR1 40%@2yr for CR1
HCT-CI is 0, and NRM~20%
Risk Groups
Low CML in CPRAAA
Int CML in APCML BP then CPAcute leukemia in remissionLymphoma in remissionRAEBCLLPNH
High CML in BPAcute leukemia in relapseLymphoma in relapseRAEB-tMyelomaSolid cancer
Category
Score Probability of Death
1 9-16 <25%
2 17-23 25-50%
3 24-30 50-75%
4 31-44 >75%
PAM score is:◦ 17 if RIST◦ 20 if myeloablative (non-TBI)◦ 24 if myeloablative
(TBI 12 Gy)